Licarbazepine

Summary

Licarbazepine (CHEMBL1067) is a phase-3 clinical-stage small-molecule sodium channel blocker; indicated across 3 conditions including bipolar disorder and epilepsy.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 3 conditions
• Clinical trials: 8
• Chemistry: 254.28 Da · C15H14N2O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1067
Name	Licarbazepine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	114709
ChEBI	CHEBI:701
Molecular formula	C15H14N2O2
Molecular weight	254.28
InChIKey	BMPDWHIDQYTSHX-UHFFFAOYSA-N

SMILES: C1C(C2=CC=CC=C2N(C3=CC=CC=C31)C(=O)N)O

IUPAC name: 5-hydroxy-5,6-dihydrobenzo[b][1]benzazepine-11-carboxamide

ChEBI definition: A dibenzoazepine that is 5H-dibenzo[b,f]azepine, reduced across the C-10,11 positions and carrying a carbamoyl substituent at the azepine nitrogen and a hydroxy function at C-10. A voltage-gated sodium channel blocker with anticonvulsant and mood-stabilizing effects, it is related to oxcarbazepine and is an active metabolite of oxcarbazepine.

Pharmacological roles (ChEBI): sodium channel blocker, anticonvulsant, drug allergen.

Also known as: Licarbazepina, Licarbazepine, LICARBAZEPINE, LicarbazepineÊ, LicarbazepineÂ, licarbazepine

Patent coverage: 107 distinct patent families (254 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 187 (74%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bipolar disorder	3	MONDO:0004985	EFO:0009963
epilepsy	1	MONDO:0005027	EFO:0000474

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE3	5
PHASE1	2
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00139594	PHASE4	COMPLETED	Open Label Extension Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder
NCT00099229	PHASE3	COMPLETED	Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder
NCT00107926	PHASE3	COMPLETED	Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder
NCT00107939	PHASE3	COMPLETED	Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder
NCT00228059	PHASE3	COMPLETED	An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder.
NCT00238485	PHASE3	COMPLETED	An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750-2000 mg/d in the Treatment of Manic Episodes of Bipolar I Disorder
NCT00424671	PHASE1	COMPLETED	Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Metabolism of a Single Dose of Licarbazepine
NCT00426036	PHASE1	COMPLETED	Effect of Severe Renal Impairment on Pharmacokinetics and Metabolism of a Single Administration of Licarbazepine

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 0 clinical and 2 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).